Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
about
ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetaseHalofuginone enhances the radiation sensitivity of human tumor cell linesFollistatin is induced by ionizing radiation and potentially predictive of radiosensitivity in radiation-induced fibrosis patient derived fibroblasts.Targeting tumor cell motility to prevent metastasis.Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.Characterization of Plasmodium liver stage inhibition by halofuginone.Follistatin attenuates radiation-induced fibrosis in a murine modelSurgical stress resistance induced by single amino acid deprivation requires Gcn2 in mice.Adult human sarcomas. II. Medical oncology.Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment?Halofuginone suppresses growth of human uterine leiomyoma cells in a mouse xenograft modelAminoacyl-tRNA synthetases as drug targets in eukaryotic parasites.Plant-derived anticancer agents: a promising treatment for bone metastasis.Halofuginone - the multifaceted molecule.Hydrolysable tannins of tropical almond show antifibrotic effects in TGF-β1-induced hepatic stellate cells.A Novel Synthesis of the Efficient Anti-Coccidial Drug Halofuginone Hydrobromide.Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis.The preventive effect of halofuginone on posterior glottic stenosis in a rabbit model.Cross-contamination of non-target feedingstuffs by halofuginone hydrobromide authorised for use as a feed additive - Scientific opinion of the Panel on Contaminants in the Food ChainNeuronal Transforming Growth Factor beta Signaling via SMAD3 Contributes to Pain in Animal Models of Chronic Pancreatitis.Halofuginone Attenuates Osteoarthritis by Rescuing Bone Remodeling in Subchondral Bone Through Oral Gavage.
P2860
Q27675589-3F2A0C95-679B-4146-A68C-7F420F5E2EA2Q33717031-0DEE6F89-3EF2-4CAE-A6B6-2D47F7CB7055Q35035034-CB8CFDBC-3F97-46A2-9007-74895EAA4F43Q35095152-2249A70F-5BF2-41BE-A051-3471095C1F0CQ35552714-0E542760-9897-4266-8C2C-F8170239625FQ35983791-C368E9E9-1DBE-48D4-921F-3DB8B60AA32EQ36310562-A927BDF3-A720-4322-BE86-ADB3B227FADAQ36503034-1FEE2660-DEAA-45FF-9376-B93F4EBB9A16Q36731430-0B343A07-3989-45B7-AB50-7E32BDA8273AQ36840263-2D3274BD-1C27-4931-9B60-44A11345944FQ36991838-5107DD1C-670C-490B-A39C-DC2216BCB68EQ37613101-3D97C541-DB72-40FC-A972-F9D9B914F2D7Q37640924-B275E415-45DC-4F88-B17C-E78C4CF75321Q38311322-863CA34E-1282-4D7E-8F92-B542C1873976Q38946850-3C0A2347-DBA7-467A-AB03-29E0D82B8266Q40152371-693D7593-12EE-4867-9B86-7CFBAE9A903DQ43831700-6E8E69A3-87A9-4E56-BC92-A144E5133F4AQ46514225-C81FB94D-89B7-4622-9AF0-8EDDDB1DE4B5Q47145363-52F4F447-12D5-42E2-803A-4EE6F23E7829Q51744338-921C029B-1C07-4F3F-9B85-2A2C9C8386E0Q52595224-8FBD2C90-66C8-4254-B84C-7453D31D3C2E
P2860
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase I and pharmacokinetic st ...... s with advanced solid tumours.
@ast
Phase I and pharmacokinetic st ...... s with advanced solid tumours.
@en
type
label
Phase I and pharmacokinetic st ...... s with advanced solid tumours.
@ast
Phase I and pharmacokinetic st ...... s with advanced solid tumours.
@en
prefLabel
Phase I and pharmacokinetic st ...... s with advanced solid tumours.
@ast
Phase I and pharmacokinetic st ...... s with advanced solid tumours.
@en
P2093
P1476
Phase I and pharmacokinetic st ...... s with advanced solid tumours.
@en
P2093
A van Oosterom
C J A Punt
EORTC New Drug Development Group (NDDG)
M J A de Jonge
S Marréaud
P304
P356
10.1016/J.EJCA.2005.12.027
P577
2006-07-03T00:00:00Z